Antengene Corporation Limited announced that XPOVIO® has been added to the National Reimbursement Drug List for the treatment of adult patients with relapsed or refractory multiple myeloma whose disease is refractory to at least one proteasome inhibitors, one immunomodulatory agent, and an anti-CD38 monoclonal antibody.
